Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) that support the company's plans for an adaptive Phase 2 field study of TNX-4800, its long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. This regulatory feedback is a crucial milestone for the program, as it provides a pathway for clinical development of a preventive treatment for a disease that affects hundreds of thousands of Americans each year.
The planned randomized, placebo-controlled study is expected to enroll approximately 3,300 adults over two Lyme disease seasons, with the primary goal of evaluating the efficacy of TNX-4800 in preventing Lyme disease through six months after dosing. According to the company, manufacturing of the investigational product is on track for delivery to study sites in the first quarter of 2027. TNX-4800 is being developed as a seasonal immunopreventative administered as two subcutaneous injections three months apart, potentially providing protection throughout the U.S. Lyme disease season, which typically runs from spring through fall.
Lyme disease, caused by the bacterium Borrelia burgdorferi and transmitted through the bite of infected black-legged ticks, is the most common vector-borne disease in the United States. The Centers for Disease Control and Prevention estimates that approximately 476,000 Americans are diagnosed and treated for Lyme disease each year. Current prevention strategies focus on personal protective measures, such as insect repellents and tick checks, but there is no vaccine available for humans. The development of TNX-4800 represents a potential significant advancement in public health, offering a passive immunization approach that could provide immediate and sustained protection during high-risk periods.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved as the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
In addition to its CNS portfolio, Tonix is advancing a pipeline of immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The FDA's feedback on the TNX-4800 program is a positive signal for the company's immunology pipeline, which aims to address significant unmet needs in infectious disease and transplantation.
The announcement underscores Tonix's commitment to developing innovative therapies for conditions with high unmet medical need. With the FDA's guidance in hand, the company is poised to move forward with the Phase 2 study, which will provide critical data on the safety and efficacy of TNX-4800. If successful, this candidate could become a vital tool in the fight against Lyme disease, offering a new option for individuals at risk of tick bites during the active season.
